Know2eat

Akkermansia muciniphila

Akkermansia muciniphila

Probiotics & Gut

What akkermansia muciniphila may help with

Ranked by how strong the human evidence is — best supported first.

Best supportedInsulin sensitivityLimited evidence· 4 sources

Then, in order

About Akkermansia muciniphila

A mucin-degrading bacterium that lives in the intestinal mucus layer and is consistently less abundant in people with obesity and type 2 diabetes. Sold as a live or, more often, a pasteurised preparation.

Akkermansia is the most prominent of the "next-generation" probiotics, and its story runs the wrong way round from most: the observational and mouse data came first and were striking, and the human evidence is one three-month exploratory trial in 32 overweight volunteers reporting improvements in insulin sensitivity and some liver markers, with pasteurised cells performing better than live ones. That is a promising pilot, not a result. Everything sold today rests on it, and on the widespread and much older observation that abundance of this organism correlates with better metabolic health — correlation which may equally reflect diet, medication or the state of the mucus layer.

Sold as
Capsule (pasteurised cells), Live culture capsule
Standardised to
Cells per dose, typically 10^10; pasteurised products are not viable organisms — a product without this marker may not resemble what was studied.
Also known as
Akkermansia, Pasteurised Akkermansia, Next-generation probiotic

Regulation: Pasteurised Akkermansia muciniphila was authorised as a novel food in the EU in 2021 with specified conditions of use, and is sold in the US as a dietary supplement with no pre-market efficacy review. Novel food authorisation is a safety assessment, not a finding of efficacy — a distinction the marketing tends to blur.

What the research used

The amounts, forms and durations published trials of Akkermansia muciniphila actually administered.

These are the amounts published trials administered — not a recommendation, and not a dose to copy. Trial participants were screened, supervised and given a characterised preparation. What is in a retail bottle is frequently not what was studied, and the amount that suits one person is not general advice.

  • Studied for Metabolic markers in overweight adults

    10 billion cells

    Limited

    Pasteurised Akkermansia daily · 3 months

    From a single exploratory trial in 32 people, designed primarily to test safety and feasibility. Its metabolic findings were secondary and have not been replicated in a larger trial.

This is general information about food, not medical advice. It cannot diagnose, treat or replace guidance from a clinician who knows your history.

When it was taken

Each window says whether a trial compared it against an alternative, or whether it is convention and pharmacology. Most timing advice is the second kind.

None of the timings below were directly compared in a trial. They reflect how the research happened to dose, or what the pharmacology implies — which is not the same as a timing being better.

  • Any time

    Not enough

    No timing comparison exists. Pasteurised preparations are not live, so gastric survival is not the issue it is for other probiotics.

    Timing was not directly compared. This reflects convention or how the compound behaves in the body, not a trial showing this window works better.

The evidence in depth

Best supported: Limited

What each association actually rests on, and the papers behind it. A rating describes the state of the research, not how promising the supplement sounds. How we rate evidence.

Insulin sensitivity

Blood Sugar & Metabolic Health
Limited evidence

One small exploratory trial reported improved insulin sensitivity and reduced insulinaemia with pasteurised Akkermansia over three months, alongside small reductions in liver enzymes. A single pilot study in 32 people is a reason to run a larger trial, not a basis for a claim.

What may be going on: A specific outer membrane protein, Amuc_1100, interacts with Toll-like receptor 2 and has been linked in mice to improved gut barrier function. This mechanism has not been demonstrated to operate in humans.

Limited evidence. Early human work, or mostly lab and animal research.

View the 4 sources

Deep research mode adds each paper’s own conclusion and stated limitations.

Gut microbiome

Gut & Digestive Health
Not enough evidence

Lower abundance of Akkermansia is consistently associated with obesity, diabetes and inflammatory bowel disease in cross-sectional studies. Whether supplementing it changes anything, and in which direction the original association runs, is unresolved.

Not enough evidence. Not enough human research to say anything useful yet.

View the 3 sources

Deep research mode adds each paper’s own conclusion and stated limitations.

Things to know

Interactions, contraindications and dose limits, most serious first. Concentrated extracts interact with medication in ways the whole plant does not, so this section carries more weight here than it does on a food page.

  • Avoid

    Immunocompromise and critical illness

    Live preparations carry the standard probiotic contraindications in immunosuppressed and critically ill people. There is also very little long-term human safety data on this organism at all, since it entered the market recently.

  • Worth knowing

    One small trial underpins the whole category

    The human evidence is a three-month exploratory study in 32 volunteers. Marketing that describes Akkermansia as a demonstrated metabolic intervention is describing mouse data and a pilot.

  • Worth knowing

    A mucin degrader in a damaged gut

    Akkermansia lives by consuming intestinal mucus. In animal models of colitis and in some infection models, higher abundance has been associated with worse outcomes, which is a reason for caution in people with active inflammatory bowel disease or a compromised mucus layer.

Evidence ratings on this page: 1 limited evidence, 1 not enough evidence.

Supplements are sold in the US without pre-market review of efficacy or safety. Nothing on this page is a recommendation to take Akkermansia muciniphila, or a dose to follow.